Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma Holdings Statistics

Total Valuation

XERS has a market cap or net worth of $479.78 million. The enterprise value is $672.01 million.

Market Cap	479.78M
Enterprise Value	672.01M

Important Dates

The next confirmed earnings date is Friday, November 8, 2024, before market open.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	n/a

Share Statistics

XERS has 149.00 million shares outstanding. The number of shares has increased by 3.38% in one year.

Shares Outstanding	149.00M
Shares Change (YoY)	+3.38%
Shares Change (QoQ)	+5.57%
Owned by Insiders (%)	4.42%
Owned by Institutions (%)	41.41%
Float	142.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.51
Forward PS	2.25
PB Ratio	n/a
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	3.70
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.26

Current Ratio	2.26
Quick Ratio	1.59
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1.29

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-7.04%
Return on Capital (ROIC)	-9.50%
Revenue Per Employee	$481,202
Profits Per Employee	-$157,995
Employee Count	377
Asset Turnover	0.55
Inventory Turnover	0.74

Taxes

In the past 12 months, XERS has paid $482,000 in taxes.

Income Tax	482,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +69.47% in the last 52 weeks. The beta is 1.28, so XERS's price volatility has been higher than the market average.

Beta (5Y)	1.28
52-Week Price Change	+69.47%
50-Day Moving Average	2.92
200-Day Moving Average	2.46
Relative Strength Index (RSI)	66.22
Average Volume (20 Days)	1,140,667

Short Selling Information

The latest short interest is 11.57 million, so 7.76% of the outstanding shares have been sold short.

Short Interest	11.57M
Short Previous Month	11.09M
Short % of Shares Out	7.76%
Short % of Float	8.12%
Short Ratio (days to cover)	8.56

Income Statement

In the last 12 months, XERS had revenue of $181.41 million and -$59.56 million in losses. Loss per share was -$0.42.

Revenue	181.41M
Gross Profit	151.88M
Operating Income	-37.19M
Pretax Income	-59.08M
Net Income	-59.56M
EBITDA	-25.00M
EBIT	-37.19M
Loss Per Share	-$0.42

Balance Sheet

The company has $77.57 million in cash and $269.80 million in debt, giving a net cash position of -$192.24 million or -$1.29 per share.

Cash & Cash Equivalents	77.57M
Total Debt	269.80M
Net Cash	-192.24M
Net Cash Per Share	-$1.29
Equity (Book Value)	-19.29M
Book Value Per Share	-0.13
Working Capital	94.85M

Cash Flow

In the last 12 months, operating cash flow was -$37.79 million and capital expenditures -$1.04 million, giving a free cash flow of -$38.83 million.

Operating Cash Flow	-37.79M
Capital Expenditures	-1.04M
Free Cash Flow	-38.83M
FCF Per Share	-$0.26

Margins

Gross margin is 83.72%, with operating and profit margins of -20.50% and -32.83%.

Gross Margin	83.72%
Operating Margin	-20.50%
Pretax Margin	-32.57%
Profit Margin	-32.83%
EBITDA Margin	-13.78%
EBIT Margin	-20.50%
FCF Margin	-21.40%

Dividends & Yields

XERS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.38%
Shareholder Yield	-3.38%
Earnings Yield	-12.41%
FCF Yield	-8.09%

Analyst Forecast

The average price target for XERS is $4.67, which is 45.03% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$4.67
Price Target Difference	45.03%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	17.30%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

XERS has an Altman Z-Score of -1.71 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.71
Piotroski F-Score	4